RE
RUBY

RBC Europe’s Rubius Therapeutics, Inc RUBY Stock Holding History

RBC Europe’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-635
Closed -$9.99K – 1085
2019
Q2 		$9.99K Hold
635
– – ﹤0.01% 804
2019
Q1 		$11.5K Hold
635
– – ﹤0.01% 784
2018
Q4 		$10.2K Buy
+635
New +$11.6K ﹤0.01% 780

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

RBC Europe's RUBY Position: Q3 2019 in Review

RBC Europe sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2019, closing a stake of 635 shares — an estimated $9.99K sold.

RBC Europe first reported a position in RUBY in Q4 2018 and held it in 3 quarters. The position peaked at $11.5K in Q1 2019. 75 funds tracked by Wall St. Rank hold RUBY as of Q3 2019.

  • RBC Europe reported no remaining Rubius Therapeutics, Inc position as of Q3 2019 after selling out during the quarter.
  • RBC Europe sold 635 Rubius Therapeutics, Inc shares in Q3 2019, an estimated $9.99K.
  • RBC Europe first reported a position in Rubius Therapeutics, Inc in Q4 2018 and held it in 3 quarters.
  • RBC Europe's Rubius Therapeutics, Inc position peaked at $11.5K in Q1 2019.
  • 75 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2019.

Based on RBC Europe's 13F filing for Q3 2019, filed 9 Nov 2023.